Abstract 2245: Fever-range whole-body thermochemotherapy (FR-WB-TT + chemo-biotherapy) can induce long-duration response in both metastatic small-cell lung cancer (SCLCA) and other chemotherapy resistant neuroendocrine cancers

2011 ◽  
Author(s):  
Joan Marie C Bull ◽  
Theresa Dancsak ◽  
Young Su ◽  
Shuang Li ◽  
Michael D. Redwine ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Whole Body ◽  
Small Cell Lung ◽  
Long Duration ◽  
Neuroendocrine Cancers

scholarly journals Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1634
Author(s):  
Lavinia Monaco ◽  
Maria Gemelli ◽  
Irene Gotuzzo ◽  
Matteo Bauckneht ◽  
Cinzia Crivellaro ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Checkpoint Inhibitors ◽  
Complete Response ◽  
Metabolic Tumor Volume ◽  
Small Cell ◽  
Whole Body ◽  
Small Cell Lung ◽  
Nsclc Patients

Immune-checkpoint inhibitors (ICIs) have been proven to have great efficacy in non-small cell lung cancer (NSCLC) as single agents or in combination therapy, being capable to induce deep and durable remission. However, severe adverse events may occur and about 40% of patients do not benefit from the treatment. Predictive factors of response to ICIs are needed in order to customize treatment. The aim of this study is to evaluate the correlation between quantitative positron emission tomography (PET) parameters defined before starting ICI therapy and responses to treatment and patient outcome. We retrospectively analyzed 92 NSCLC patients treated with nivolumab, pembrolizumab or atezolizumab. Basal PET/computed tomography (CT) scan parameters (whole-body metabolic tumor volume—wMTV, total lesion glycolysis—wTLG, higher standardized uptake volume maximum and mean—SUVmax and SUVmean) were calculated for each patient and correlated with outcomes. Patients who achieved disease control (complete response + partial response + stable disease) had significantly lower MTV median values than patients who had not (progressive disease) (77 vs. 160.2, p = 0.039). Furthermore, patients with MTV and TLG values lower than the median values had improved OS compared to patients with higher MTV and TLG (p = 0.03 and 0.05, respectively). No relation was found between the other parameters and outcome. In conclusion, baseline metabolic tumor burden, measured with MTV, might be an independent predictor of treatment response to ICI and a prognostic biomarker in NSCLC patients.

scholarly journals C2-06: Integrated PET/CT versus 3T whole body MR imaging: efficacy comparison in non-small cell lung cancer staging

2007 ◽  
Vol 2 (8) ◽  
pp. S363-S364
Author(s):  
Kyung-Min Shin ◽  
Chin A. Yi ◽  
Kyung Soo Lee ◽  
Byung-Tae Kim ◽  
Hojoong Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Mr Imaging ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cancer Staging ◽  
Small Cell ◽  
Whole Body ◽  
Small Cell Lung ◽  
Pet Ct

Yield of Total Body GA-67 Scintigraphy in the Staging of Non-Small Cell Lung Cancer

1989 ◽  
Vol 75 (1) ◽  
pp. 38-42 ◽  
Author(s):  
Gianfranco Buccheri ◽  
Ferruccio Vola ◽  
Domenico Ferrigno ◽  
Antonio Curcio
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
False Negative ◽  
Small Cell ◽  
Whole Body ◽  
Small Cell Lung ◽  
Mediastinal Disease ◽  
Metastatic Sites ◽  
Sensitivity Specificity

One hundred and one patients with histologically proved non-small cell lung cancer underwent whole body gallium-67 (TB Ga-67) scintigraphy as a part of their routine pretreatment evaluation. Twenty-eight of these patients were subsequently operated and pathologically staged for hilar and mediastinal disease. Two other patients underwent mediastinoscopy, but were judged unresectable at that time. All had computed tomography (CT) of the thorax, as well as radionuclide or CT scans of suspicious metastatic areas, and were carefully followed-up. When possible, a biopsy was performed of each suspected metastasis. Primary lung tumors concentrated Ga-67 in 94 patients. Sensitivity, specificity, and accuracy for hilar and mediastinal node metastases were 58%, 89%, and 77%, respectively. There were no false-negative gallium scans as regards secondary involvement of both liver and bone, whereas only 1 of the 4 brain metastases was detected by the technique. Sensitivity, specificity, and accuracy for all metastatic sites were 82%, 38%, and 56%, respectively. Fifty-five patients were classified as having a more advanced stage of disease by TB Ga-67 scintigraphy than at the initial clinical evaluation. However, 42 gallium-staged patients were ultimately re-classified differently according to all available clinical data. Using TB Ga-67 scintigraphy, 21 patients were found to have occult metastases which would not otherwise have been recognized; for the above reason, an unnecessary intervention was avoided in 6 of them.

Non–Small Cell Lung Cancer: Whole-Body MR Examination for M-Stage Assessment—Utility for Whole-Body Diffusion-weighted Imaging Compared with Integrated FDG PET/CT

Radiology ◽  
2008 ◽  
Vol 248 (2) ◽  
pp. 643-654 ◽  
Author(s):  
Yoshiharu Ohno ◽  
Hisanobu Koyama ◽  
Yumiko Onishi ◽  
Daisuke Takenaka ◽  
Munenobu Nogami ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Diffusion Weighted Imaging ◽  
Small Cell ◽  
Whole Body ◽  
Small Cell Lung ◽  
Pet Ct ◽  
Fdg Pet Ct

Incidence of non-metastatic extrathoracic lesions detected by whole-body FDG PET-CT imaging in patients with non-small-cell lung cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7186-7186
Author(s):  
D. Lardinois ◽  
H. C. Steinert ◽  
M. Tutic ◽  
G. Görres ◽  
R. Stahel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Ct Imaging ◽  
Small Cell ◽  
Whole Body ◽  
Small Cell Lung ◽  
Pet Ct ◽  
Fdg Pet Ct

Prognostic value of different standard uptake values (SUV) of primary tumor measured with FDG-PET in resectable non-small cell lung cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 7214-7214
Author(s):  
W. K. De Jong ◽  
H. F. Van der Heijden ◽  
J. Pruim ◽  
W. J. Oyen ◽  
H. J. Groen
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Cell Lung Cancer ◽  
Primary Tumor ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Small Cell ◽  
Whole Body ◽  
Small Cell Lung

7214 Background: The SUV is a measure for the preferential uptake of a radiopharmaceutical in a tumor compared with a homogenous distribution in a body. SUV can be based on the maximum value (SUVmax) or on the mean value in a region outlined by isodensity contours, e.g., 70% and 50%. The prognostic value of the different SUVs in non-small cell lung cancer (NSCLC) is not clear. We evaluated the prognostic value of SUVmax, SUV 70% and SUV 50% in patients (pts) with resectable NSCLC. Methods: All consecutive pts who underwent an attenuation corrected whole body FDG-PET scan were selected. All data were reconstructed iteratively. Only pts with stage I through IIIA NSCLC were included. By adjusting the isocontour in the region of interest, the SUVmax, SUV 70% and SUV 50% of the primary tumor were calculated. Cox regression analysis was used to calculate the relation between the different SUVs and survival. Results: Eighty-four pts (67 males, median age 64 years, range 38–86) were included. Histology was squamous cell carcinoma (n = 43), adenocarcinoma (n = 27), large cell carcinoma (n = 13), and 1 patient with bronchoalveolar carcinoma. Nineteen pts had stage IA, 28 stage IB, 4 stage IIA, 19 stage IIB, and 14 stage IIIA. Median (range) SUVmax, SUV 70%, and SUV 50% were 6.9 (1.6–32.5), 5.5 (1.0–23.2), and 4.5 (0.9–21.9), respectively. Analysis of residuals of SUVmax as a continuous variable suggests no cut-off point and no indication of time-dependency. By univariate analysis, all pts with a SUV higher than the median value had a worse survival than pts with a SUV lower than median (Hazard ratio’s for SUVmax, SUV70% and SUV 50% were 2.3 (p = 0.024), 2.5 (p = 0.015), and 2.7 (p = 0.010), respectively). Conclusions: SUVmax, SUV 70% and SUV 50% measured with FDG-PET have a similar prognostic impact. No cut-off point for SUVmax has been observed. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document